Akademik Veri Yönetim Sistemi
ARQUIVOS BRASILEIROS DE CARDIOLOGIA, cilt.121, sa.11, ss.20240202, 2024 (SCI-Expanded, Scopus)
Background: Dual antiplatelet therapy (DAPT) is the treatment of choice for patients with acute and chroniccoronary syndromes as it reduces mortality and prevents recurrent thrombotic complications. The assessment ofboth ischaemic burden and bleeding risk is crucial in deciding which DAPT to choose and how long it should becontinued.
Objectives: The aim of our study was to perform prospective clinical follow-up of patients receiving fixed-dosecombination therapy (ASA 75 mg + clopidogrel 75 mg). Our study is a multicentric, cross-sectional, observational,cohort study.
Methods: A total of 1500 patients who were started on fixed-dose combination DAPT for acute or chronic coronarysyndrome were included in the study. Primary endpoints were hospitalization for any reason, hospitalization forcardiovascular cause, acute myocardial infarction, stent thrombosis, target vessel revascularization and bleeding;the secondary endpoints were death for any reason or cardiovascular cause and stroke. The significance leveladopted in the statistical analysis was 5%.
Results: Median age was 63 years; 78.5% of the patients were receiving DAPT treatment for acute coronarysyndrome. The rates of hospitalization for cardiovascular reasons, acute myocardial infartion, stent thrombosisand target-vessel revascularization were 7.9%, 2.3%, 1.3% and 4.2%, respectively. While the rate of BARC type 1bleeding was 3.3%, the rate of BARC type 5, 3, or 2 bleeding was 0.6%. The secondary endpoints which were deathfrom any cause, cardiovascular death and stroke were 0.5%, 0.3% and 0.3%, respectively.
Conclusion: Our study shows that fixed-dose combination therapy is effective and safe in appropriately selectedpatients with acute or chronic coronary syndromes.